Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits

• Ngā kaituhi matua: Darren K. McGuire (Author), Silvio E. Inzucchi (Author), Odd Erik Johansen (Author), Julio Rosenstock (Author), Jyothis T. George (Author), Nikolaus Marx (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2021-12-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Hyperglycemia is an undisputed epidemiological risk factor for microvascular complications in both type 1 and type 2 diabetes, integral in their causal pathways. Importantly, interventions that reduce the hyperglycemic burden in patients with either type of diabetes reduce the risk of microvascular...